Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**RPL27AP9 (ribosomal protein L27a pseudogene 9)** is a processed pseudogene derived from the *RPL27A* gene, which encodes the 60S ribosomal protein L27a as part of the large ribosomal subunit[4][2]. Pseudogenes are sequences that resemble functional genes but are typically non-functional due to mutations, truncations, or lack of regulatory elements necessary for gene expression[2]. RPL27AP9 is one of several ribosomal protein L27a pseudogenes found dispersed throughout the human genome. It does not encode a functional protein and is not involved in cellular processes, disease, or therapeutic intervention. While some processed pseudogenes can be transcribed or even translated, there is no evidence for any functional or pathological role for RPL27AP9. Its presence reflects past evolutionary events such as retrotransposition rather than current biological activity[2]. **Key facts** - The canonical gene (RPL27A) encodes a ribosomal protein important for protein synthesis in the cell[1][5]. - RPL27AP9 is a *pseudogene*, meaning it does not produce a functional ribosomal protein and is not a therapeutic target nor a molecular entity with biological or disease roles[4][2]. - No drugs, biomarkers, mechanism of action, or safety concerns are associated with RPL27AP9. - The name and abbreviation conform to accepted gene nomenclature. If you require information on the *functional* ribosomal protein (RPL27A), it is a structural component of the ribosome, involved in translation and protein synthesis, but the pseudogene RPL27AP9 itself is biologically inert[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ribosomal protein L27a pseudogene 9 (RPL27AP9).